Innovative approach to life

Our mission:

Giving a part of ourselves, we give people an opportunity to live a productive life. Our innovative approach allows us to create effective solutions that provide confidence in the future. We are the team of like-minded people who help people live and think in a different way!

Our mission: Giving a part of ourselves, we give people an opportunity to live a productive life. Our innovative approach allows us to create effective solutions that provide confidence in the future. We are the team of like-minded people who help people live and think in a different way! Dear friends, Promo-Med LLC. Company was established in September 2005 and today it is one of the most dynamic in the pharmaceutical industry. The Company’s goal is to create and maintain an image of the Russian pharmaceutical brand as a new category of product, which is of high quality, accessible, trusted by both doctors and patients. The Company closely monitors the development of the Russian pharmaceutical market and keeps track of the most promising segments of the market, constantly enriching its portfolio of products. Promo-Med LLC. is a highly effective and flexible Company that allows it to respond quickly to changes or demands of the current pharmaceutical market, performing with the greatest benefit to investors and partners.

Elena Palevskaya CEO

Promo-Med is a new-generation innovative company introducing its European quality medicines at fair price to the Russian market

The Company was founded in September, 2005 by Russian and foreign investors.

Company’s first steps started from the development, registration and production of medicinal products Revokarin® and Neosmektin® in 2005.

In 2006 – just within 10 months of Neosmektin® lauch – the drug has conquered 3.4% of the market share of its main competitor – Smecta (manufactured by Beaufour Ipsen International, France). In 2006 Neosmektin® was sold successfully to Pharmstandard OJSC.

Meridia patent expired on the 18th of December 2007. And on the 19th of December 2007 Reduxin®, a generic, showed up at retailers in Russia.

Trademark Reduxin® made a breakthrough, having been moved from the 14th in 2008 to the 6th place in 2009 in terms of volume sales in cash equivalent among TOP 100 Trademarks in Retail Industry on the Russian pharmaceutical market.

In 2009 a new cardiac drug Valsaforce®, the first generic of the sartan, was launched.

In March 2009 the Company’s CEO Palevskaya E.Yu. entered TOP 20 Most Influential Women in Business in the annual project Careers.

In 2010 Medomexi® , a new multi-purpose cytoprotector for the neurogroup, was launched on the market.

In 2011 a series of new drugs were launched:

Melfor® - multi-purpose cytoprotector for the cardiac group.

Raylis® – medicine for the treatment and prevention of erectile dysfunction. Thus, in 2011 the Company gained a unique business package: Medomexi® (ampoules+tablets) and Melfor® (ampoules + capsules).

The Company also acquired a joint possession right for brand Taufon.

Mission

The Promo-Med mission is to create and maintain the image of the Russian pharmaceutical brand as a new product category – high quality, affordable, reliable among doctors and patients.

Corporative values: Complete professionalism, liability, innovativeness and professionalism again.

4 components of our success: Ambitious and professional team. Excellent knowledge of the pharmaceutical market. Personal scientific research. Promptness of making solutions.

The Company’s medicines are available in 87 Russian cities: Moscow, St. Petersburg, Nizhny Novgorod, Murmansk, Novosibirsk, Ekaterinburg, Samara, Krasnodar, Rostov-on-Don, Veliky Novgorod, Tula, Omsk, Volgograd and others

Distribution

The company has a broad network of field sales representatives all over the directions across the entire territory of Russia

Areas of focus

Our knowledge and resources are focused on 6 main therapeutic groups:

We produce innovative and effective drugs with improved safety profiles and more convenient administration.

We continuously conduct all-Russian clinical trials and non-intervention studies of our products to assess efficiency and safety of our products.

ENDOCRINOLOGY

CARDIOLOGY GYNECOLOGY NEUROLOGY

GASTROENTEROLOGY UROLOGY

Research

Efficiency and safety of the drugs manufactured by our company are confirmed by authoritative clinical trials:

“Experience in Reduxin® (sibutramin) in patients with metabolic syndrom” (S.А. Butrova, М.А. Berkovskaya, К.А. Komshilova) Federal State Institute Endocrinology Research Centre RMT (Moscow).

“Reduxin® is a new solution for old problems!” (Т.Yu. Demidova, MD, Professor of Endocrinology and Diabetology Department with endocrine surgery of Russian Medical Academy of Post-Graduate Education of Roszravnadzor).

“Dynamics of body weight reduction in obese patients (12 weeks)” (Professor А.М. Mkrtumyan, Е.V. Biryukova, N.V. Markina) Endocrinology and Diabetology Department of Moscow State University of Medicine and Dentistry (MSUMD).

“Dynamics of BMI in patients with type 2 diabetes and obesity” (Professor М.B. Antsiferov) Moscow endocrinological dispensary.

“Open-label, single-arm, multicentere clinical study of efficacy and safety of Raylis® in patients with mild to moderate erectile dysfunction” (Professor D.Yu. Pushkar, MD) Urology Department of the Faculty of Medicine (MSUMD).

“Clinical efficiency and safety of Valsaforce® in patients with hypertension and chronic renal disease” (M.L. Maximov, O.V. Dralova, A.S. Ermolaeva ) Clinical Pharmacology and Propedeutics Department of the Faculty of Medicine of The I.M. Sechenov Moscow Medical Academy.

Annual increase of the Company’s sales is more than 100% grouse from 2009 to present time

Achievements

In 2006 – just within 10 months of Neosmektin® launch — the drug has conquered 3.4% of the market share of its main competitor — Smecta (manufactured by Beaufour Ipsen International, France).

In March 2009 the Company’s CEO Palevskaya E.Yu. entered TOP 20 Most Influential Women in Business in the annual project Careers.

On April 2011, our company became a winner of the All-Russian Economic Project Leaders of modernization in a nomination The Enterprise of Year 2011.

Pharmexpert Analytics and Consulting LLC. selected TM Reduxin® the Month’s Best drug of July 2011 as it demonstrated the best growth of sales volume of all Russian drugs among TOP 100 Tradenames in Retail Industry on the pharmaceutical market. Sales gain of Reduxin® in May in the current year compared to 2011 was +73.7% and +51.2% in monetary terms and in natural, respectively.

A new production protection system has been created. Each hologram has its own unique code. This code is essential for the inspections aimed at products’ identification, monitoring and protection.

In 2011 Reduxin® entered TOP 10 Best Volume Sales (in USD mln) in retail industry of the Russian pharmaceutical market for the first half of the year, according to Pharmexpert Analytics and Consulting LLC.

Professional Development

Our cooperation with Brand Learning started in September 2011 with the development of marketing skills and establishment of corporate culture.

Together we share the importance of forming the organization which is customer-oriented, as well as the development of marketing potential. Together we transform marketing skills into our company’s performance by developing and training staff to use new approach to create successful brands.

Partners

Общество эндокринологов

ОБЩЕСТВО УРОЛОГОВ

Общество кардиологов

ООО «ОЗОН»

Success factors

Professional team.

Creation of a unique marketing strategy, comprehensive market analysis, clinical trials, studying analogue drugs and substitutes, followed by thorough branding and positioning of the products.

All products promoted by the Company are manufactured from the first-grade imported raw materials at sites being adequately inspected and selected and having advanced production facilities.

All products are manufactured according to GMP standards, which imply strict quality control at each process step.

Comprehensive programs starting from the idea up to the introduction of a new product to the market.

Training the Company’s employees with attraction of specialists of European Marketing Academy Brand Learning.

Extensive support from our partners.

All-Russia Observational Non-Interventional Program of Reduxin® Safety Monitoring (VESNA):

Efficiency Analysis:

Anthropometric data over time (weight; waist, hip, arm, neck circumferences).

BMI over time. Eating behavior dynamics. Quality of life and personal well-being

assessment (questionnaire).

Safety Monitoring:

Cardiovascular value control: Blood pressure dynamics. Heart rate. ECG.

Laboratory values: Blood plasma lipid profile. Plastic glucose level. Total bilirubin. Total protein. ALT, AST. Incidence and type of adverse events

Innovative.

Program Supervisor:chief endocrinologist of Russia

6 months — 50 000 patients36 cities of Russia

1 093 healthcare facilities2 071 doctors

Large-Scale All-Russia Observational Program MARS

Program Primary Objective–monitoring of efficiency of Raylis® in ‘real-life’ clinical practice settings.

Program Supervisor: Chief urologist of the RF Ministry of Health Care M.D.

Program participants:

1 000 urologists. 4 600 patients in 36 cities of Russia.

Program objective — 14 000 patients.

Clinical Studies of Taufon for Strengthening the Position of the Brand - Leader

I. “Randomized, open-label, two-parallel-group, prospective, interventional study of efficiency and safety of Taufon in patients with dry eye syndrome”.Primary objective: registration of new indications for Taufon (dry eye syndrome). Principal Investigator:Chief ophthalmologist of the RF Ministry of Health Care M.D.

II. “Randomized, open-label, prospective, interventional study of efficiency and safety of Taufon® in children suffering from traumatic lesions of the cornea in two parallel groups in children suffering from traumatic lesions of the cornea in two parallel groups”. Primary objective: registration of new indications for Taufon (pediatric use). Principal Investigator:Chief children's ophthalmologist of the RF Ministry of Health Care M.D.

Taufon — Leader of the Russian Market of Eye Drops for Improved Vision*

PRICE INCREASE BY

300%

* - monitoring of retail sales in packing in Russia based on Pharmexpert Analytics and Consulting LLC. data

Products

The Company manufactures 6 drug products intended for treatment of endocrine, cardiovascular, neurologic, ophthalmic, and urological conditions. 2 drug products manufactured by the Company are included in the RF list of vital and essential medicines. The Company product portfolio includes leading brands for weight-reducing treatment in Russia - Reduxin®, and the biggest-selling product for cataract conservative treatment - Taufon.

Drug product for treatment obesity – Reduxin® Antihypertensive drug product – Valsaforce® Drug product for management of neurological disorders of vascular genesis mainly – Medomexi® Drug product for improved myocardial metabolic function – Melfor® Drug product for treatment of ophthalmologic conditions – Taufon Drug product for treatment of erectile dysfunction - Raylis®

Dietary supplements.The Company manufactures nutritional supplements for health gain:

Product for eye nutrition – Taufon® VitaProducts for management of age-related changes in joints - Ellastenga® active glucosamine

Reduxin® Pharmacotherapeutic group: weight-loss medication Active substance: Sibutramine + microcrystalline cellulose

Reduxin® is the only combination product for the effective treatment of obesity, which consists of two active agents (sibutramine + MCC), which cause loss of appetite, a sense of fulness, excretion of toxins from the body, a lower profile of side effects, formation of correct eating habits and, most importantly - reduction of excess body weight.

Sibutramine binds to the brain’s hunger center, causing the feeling of hunger to decrease and eliminating a tendency to overeat (especially for the night, under stress, during PMS for women). Sibutramine also helps speed up metabolism in brown adipose tissue and promotes its gradual reduction.

Microcrystalline cellulose is a versatile sorbent that contributes to the removal of toxins from the body. It provides slow release of sibutramine from the capsules, thereby protecting the patient from adverse side effects. Weight loss is accomplished due to a decrease in appetite and a more rapid saturation with less food. Caloric value of the daily food consumption is reduced by 20-25%, which allows you to lose up to 10 or more kg in 3 months.

Presentation: Capsules 10 mg х 30. Capsules 15 mg х 30. Capsules 10 mg х 60. Capsules 15 mg х 60.

Indications: Diet-induced obesity obesity with body mass index (BMI) of 30 kg/m2 or more.Diet-induced obesity with BMI 27 kg/m2 or more, if other risk factors caused by overweight are present, such as type 2 diabetes or dyslipoproteinemia (disturbance of lipid metabolism).

Valsaforce® Pharmacotherapeutic group: AT1 receptor blocker Active substance: Valsartan

Valsartan (Valsaforce®) is a specific antagonist of angiotensin II receptor, designed for oral administration. Unlike many sartans, it is an active drug form, exerts a selective antagonistic effect on the subtype AT1 receptors. The affinity of valsartan to the subtype AT 1 receptors is about 20 000 times higher than to the subtype AT2 receptors. Treatment of patients with hypertension with valsartan causes a decrease in blood pressure not accompanied by changes in heart rate.

Indications:Hypertension. Chronic heart failure (NYHA class II to IV) in patients receiving standard therapy, including diuretics, digitalis preparations, as well as ACE inhibitors or beta-blockers (not simultaneously).

The use of Valsaforce®: Significantly reduces the risk of cardiovascular events, including reducing the likelihood of its recurrence in people who have had a stroke Contributes to regression of left ventricular hypertrophy Exerts antiatherosclerotic and protective effect on blood vessels Does not affect the erectile function in men The drug is well tolerated Adherence to treatment is much higher when compared with other groups of drugs, not least due to the substantial reduction in the incidence of cough (from 4.3% for enalapril to 0.7% for Valsaforce®). Valsaforce® is indicated for disorders of lipid and carbohydrate metabolism, with normal or reduced renal function after a stroke, transient ischemic attacks with paroxysmal or persistent atrial flutter fibrillation, peripheral circulatory disorders, chronic heart failure, disorders of erectile dysfunction before or after a complex drug therapy, poor tolerance to the major classes of cardiovascular drugs, or in case of disease symptoms persisting when those drugs are used.

Presentation: Film-coated tablets 80 mg х 28. Film-coated tablets 160 mg х 28.

Medomexi® Pharmacotherapeutic group: antioxidantActive substance: Ethylmethylhydroxypyridine succinate

Epoch of neurons revival Medomexi® has evident antioxidant and antihypoxic activity influencing on the basic links of pathogenesis of different diseases related to processes of free radical oxidation

Inhibits the free radical oxidation of membrane lipids, freely binds the peroxy radicals of lipids.

Increases activity of antioxidant enzymes responsible for formation and consumption of active forms of oxygen, in particular superoxide dismutase.

Inhibits synthesis of prostaglandins, prostacyclins, thromboxane A, and leukotrienes.

Has hypolipidemic activity, decreases specifically total cholesterol level, low-density lipoproteins, reduces cholesterol/phospholipid ratio decreasing viscosity of lipid layer. Presentation:

Intravenous and intramuscular solution 50 mg/ml. Neutral glass vials. 2 ml x 10. Neutral glass vials. 5 ml x 5. Pills 125 mg x 30.

Indications: Acute Cerebrovascular Events of ischemic type (as a part of

complex therapy). Circulatory encephalopathy. Vegetative-vascular dystonia.

Inquietude of neurotic and neurosis-like conditions.

Mild cognitive impairment of vascular genesis. Age-related reduced cognitive functions in

elderly people (derangement of memory, orientation, attention focusing).

Asthenic conditions under the influence of extreme (stress) factors.

Alcohol abstinence syndrome with prevailing neurosis-like and vegetative vascular impairment.

Acute intoxication by antipsychotic drugs.

Medomexi® is an effective drug in the complex therapy of acute and chronic strokes.

Melfor®Pharmacotherapeutic group: Metabolic agent for treatment and prevention of cardiovascular diseasesActive substance: Meldonium

The drug has a pronounced vasodilating action: stimulates vascularization of the myocardium, selectively acts on the area of ischemia. Inhibits the platelet aggregation.The drug has a cardioprotective effect: it increases myocardial contractility, normalizes myocardial metabolism by restoring the equilibrium of processes of oxygen delivery and consumption in the cells.

Presentation:Capsules 250 mg х 40.

Indications:Reduced performance efficiency, increased physical activity, to accelerate the rehabilitation during the post-operative period.As part of combined therapy of ischemic heart disease, chronic heart failure; cardialgia in the context of dyshormonal myocardial dystrophy.As part of combined treatment of acute and chronic forms of cerebrovascular disease.Combined therapy of alcohol withdrawal syndrome.Melfor® is the perfect medication for the combination therapy of cardiovascular diseases. Due to its metabolic actions, it helps increase the effect of cardiovascular therapy and restores the effectiveness of the administered antianginal therapy.It helps improve the quality of life of patients with angina pectoris, restoring myocardial performance during ischemia (reduces frequency of painful and painless angina attacks). It improves survival after myocardial infarction, reducing the recovery period after cardiovascular accident. Effectiveness of Melfor® is tested by athletes who use it before and after workouts to improve adaptation to physical exertion.

TaufonPharmacotherapeutic group: Metabolic agent Active substance: Taurine 4%

Pharmaceutical form: Eye drops.Packaging: 10 ml vials.

Taufon (taurin) is a sulphur-containing amino acid that is forming in a body during transformation of cysteine. Stimulates reparation and regeneration processes during diseases of dystrophic character and diseases following with sharp impairment of eye tissue metabolism. Favours normalization of functions of cell membranes, activation of energy and metabolic processes, keeping the cytoplasm electrolyte concentration due to accumulation of К+ and Са+, improving conditions of nervous impulse conducting.

Indications: Corneal dystrophies.Senile, radiation, traumatic and other types of cataracts.Corneal traumas (as a stimulator of reparative processes). Primary open-angle glaucoma in combination with adrenergic blocking agents.

Taufon is a unique metabolic agent which stimulates regenerative processes and improves metabolism of the eye tissues. Taufon was manufactured by the ophthalmologists of the leading research center of the country, Federal State Institution “The Helmholtz Moscow Research Institute of Eye Diseases” and successfully used in Russia and CIS countries for the treatment of various eye diseases. The use of the drug for more than 30 years confirmed its high efficacy and good tolerance. The medicine is the best-selling drug for the topical treatment of eye in the Russian Federation.

Raylis® Pharmacotherapeutic Group: the drug of vegetable origin for the treatment of erectile dysfunction Active ingredients: Panax ginseng root powder, Codonopsis pilar root powder, Panax pseudoginseng root powder, Astragalus membranaceus root powder, Epimedium extract

Pharmaceutical Form: capsules x 14 x 28.

Composition (1 capsule): Panax ginseng root powder – 50 mg.Conodopsis pilar root powder – 50 mg. Panax pseudoginseng root powder – 50 mg. Astragalus membranaceus root powder – 10 mg. Epimedium extract – 150 mg. F complex of biologically active components of the drug has a stimulating and tonic effect.

Indications: Treatment and prevention of erectile dysfunction. Recovery and enhancement of sexual function. Stimulation of sexual desire. Physical and emotional strain. Recovery after somatic and infectious diseases asthenia.

Raylis® improves erection only when there is sexual stimulation. The drug does not induce spontaneous erection without erotic stimulation. The drug can be used while taking alcohol and is characterized by a convenient dosage regimen – daily in the morning regardless of food intake.

Taufon® Vita Indication: Nutritional supplement which influences on eye function

Biologically active substance: taurine (2-2 aminoethansulfonic acid). The experiments have showed that taurine regulated the following processes in the body: Visual organ and central nervous system: taurine participates in luminous transmission in retina and regulates nerve impulse conduction velocity. Taurine is the major amino-acid component of pigmented layer of retina and exercises protection (antioxidative) and membrane-stabilizing action. Taurine deficiency is observed in severe dystrophic retinal damage and optic nerve atrophy in visual organ tissue.

Body as the whole: Ensures the transport of substances through cell membranes and supports electrolytic balance in respect of potassium, sodium, magnesium, and calcium ion balance. Activates metabolic processes, including energy, fat, and carbohydrate metabolism. Due to these effects taurine is successfully used for visual organ, cardiovascular, nervous system function improvement in patients with carbohydrate metabolism disorder and gerontologic practice. Presentation: Capsules with fill weight 350 mg that corresponds to 250 mg of taurine in 1 capsule. x 30 and x 60. Recommendations for use: In adults for improved eye tissue nutrition. In all adults doing intense work on the computer and reading on mobile computers in moving transport . During intense driving and broadcast viewing. During long open solar radiation exposure.

Ellastenga® active glucosamine Indication: Nutritional supplement – source of active glucosamine Composition: Glucosamine sulphate Biologically active substance: Glucasamine sulphate

Biologically active substance: Glucasamine sulphate. Improves joint mobility. Stimulates cartilaginous tissue regeneration. Prevents osteoarthrosis and slows down its progression. Produces moderate anti-inflammatory and analgetic effects.

Presentation: Capsules 750 mg x 30.

Recommendations for use: In case of joint diseases (osteoarthrosis) with pain. syndrome, clicking, and stiffness.

Ellastenga® contains active glucosamine in a dose of 750 mg. Glucosamine is a structural substance of cartilaginous tissue; the deficiency of glucosamine leads to the deficiency of physiologic properties of cartilage and joint disorder. Ellastenga® contains high quality glucosamine sulfate that ensures its activity and effective action. Ellastenga® compensates glucosamine contents in the body and contributes to cartilaginous tissue regeneration and easiness of movements.

Promo-Med LLC 13, Prospect Mira, Moscow, 129090, Russia

Telеfon: + 7 (495) 640-25-28 Fax: +7 (495) 640-25-27

www.promo-med.ru

Innovative approach to life